Sinphar PharmaceuticalLtd Past Earnings Performance
Past criteria checks 4/6
Sinphar PharmaceuticalLtd has been growing earnings at an average annual rate of 62%, while the Pharmaceuticals industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 6% per year. Sinphar PharmaceuticalLtd's return on equity is 10.3%, and it has net margins of 12%.
Key information
62.0%
Earnings growth rate
62.0%
EPS growth rate
Pharmaceuticals Industry Growth | 18.5% |
Revenue growth rate | 6.0% |
Return on equity | 10.3% |
Net Margin | 12.0% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Sinphar PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 3,011 | 361 | 739 | 116 |
31 Mar 24 | 2,969 | 405 | 723 | 128 |
31 Dec 23 | 2,963 | 375 | 673 | 133 |
30 Sep 23 | 2,977 | 277 | 668 | 260 |
30 Jun 23 | 2,970 | 269 | 658 | 254 |
31 Mar 23 | 2,959 | 247 | 635 | 260 |
31 Dec 22 | 2,857 | 225 | 622 | 272 |
30 Sep 22 | 2,735 | 198 | 599 | 254 |
30 Jun 22 | 2,593 | 97 | 583 | 440 |
31 Mar 22 | 2,485 | 15 | 571 | 479 |
31 Dec 21 | 2,434 | -38 | 560 | 512 |
30 Sep 21 | 2,333 | -77 | 538 | 537 |
30 Jun 21 | 2,405 | -53 | 537 | 420 |
31 Mar 21 | 2,380 | -50 | 536 | 447 |
31 Dec 20 | 2,388 | -29 | 535 | 462 |
30 Sep 20 | 2,520 | 60 | 531 | 494 |
30 Jun 20 | 2,458 | 60 | 522 | 530 |
31 Mar 20 | 2,447 | 26 | 538 | 547 |
31 Dec 19 | 2,395 | 14 | 560 | 528 |
30 Sep 19 | 2,322 | -13 | 578 | 495 |
30 Jun 19 | 2,272 | -17 | 586 | 441 |
31 Mar 19 | 2,229 | 6 | 580 | 390 |
31 Dec 18 | 2,216 | 9 | 568 | 376 |
30 Sep 18 | 2,186 | 23 | 549 | 352 |
30 Jun 18 | 2,192 | 52 | 541 | 342 |
31 Mar 18 | 2,186 | 62 | 525 | 346 |
31 Dec 17 | 2,134 | 37 | 510 | 363 |
30 Sep 17 | 2,159 | 56 | 519 | 370 |
30 Jun 17 | 2,158 | 36 | 525 | 376 |
31 Mar 17 | 2,140 | 24 | 535 | 386 |
31 Dec 16 | 2,134 | 17 | 549 | 383 |
30 Sep 16 | 2,190 | 42 | 549 | 368 |
30 Jun 16 | 2,159 | 31 | 559 | 369 |
31 Mar 16 | 2,208 | 24 | 574 | 346 |
31 Dec 15 | 2,187 | 14 | 571 | 343 |
30 Sep 15 | 2,239 | 2 | 576 | 381 |
30 Jun 15 | 2,236 | -4 | 588 | 365 |
31 Mar 15 | 2,444 | 76 | 587 | 367 |
31 Dec 14 | 2,642 | 163 | 589 | 350 |
30 Sep 14 | 2,654 | 142 | 600 | 310 |
30 Jun 14 | 2,910 | 253 | 587 | 286 |
31 Mar 14 | 2,772 | 241 | 573 | 251 |
31 Dec 13 | 2,578 | 301 | 576 | 226 |
30 Sep 13 | 2,375 | 275 | 537 | 199 |
Quality Earnings: 1734 has high quality earnings.
Growing Profit Margin: 1734's current net profit margins (12%) are higher than last year (9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1734 has become profitable over the past 5 years, growing earnings by 62% per year.
Accelerating Growth: 1734's earnings growth over the past year (34.6%) is below its 5-year average (62% per year).
Earnings vs Industry: 1734 earnings growth over the past year (34.6%) exceeded the Pharmaceuticals industry -1%.
Return on Equity
High ROE: 1734's Return on Equity (10.3%) is considered low.